| 摘要 |
<p>A percutaneously administrable preparation containing a 9-aminocyclopenta(b)quinoline, preferably 9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)-quinoline or a hydrochloride thereof, as the active ingredient and at least one percutaneous absorption accelerator selected from the group consisting of fatty acids, fatty acid esters and alcohols, preferably a glyceride of a C6-C12 saturated fatty acid.</p> |
